138
Participants
Start Date
May 30, 2013
Primary Completion Date
January 7, 2015
Study Completion Date
December 18, 2017
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
Sint Augustinus Wilrijk, Wilrijk
Memorial Sloan Kettering Cancer Center, New York
Penn State Univ. Milton S. Hershey Medical Center; MSHMC Cardiology, Hershey
Penn Presbyterian Medical Center; Abramson Cancer Center, Philadelphia
University of Pennsylvania, Philadelphia
Georgetown University, Washington D.C.
Virginia Cancer Institute, Richmond
Duke University Health Systems, Durham
Carolina BioOncology Institute; Can Therapy & Res Ctr, Huntersville
Northwest Georgia Oncology Centers P.C., Carrollton
Florida Hospital Cancer Inst, Orlando
H. Lee Moffitt Cancer Center and Research Inst., Tampa
Florida Cancer Specialists., St. Petersburg
Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie
SCRI-Tennessee Oncology, Nashville
Oncology Hematology Care, Inc., Hamilton
The University of Chicago Medical Center, Chicago
Centre Léon Bérard, Lyon
University Of Colorado, Aurora
Huntsman Cancer Institute; University of Utah, Salt Lake City
HonorHealth Research Institute - Pima Center, Scottsdale
The Angeles Clinic and Research Institute, Santa Monica Office, Santa Monica
Stanford University/Lucile Packard Children's Hospital, Palo Alto
University of Washington Seattle Cancer Care Alliance, Seattle
Yale University School Of Medicine, New Haven
Dartmouth Hitchcock Med Center; Norris Cotton Cancer Ctr, Lebanon
Ohio State Uni Hospital, Columbus
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam
Queen Mary University of London, London
Royal Marsden Hospital - Fulham; Oncology Department, London
Royal Marsden Hospital - Fulham, London
Lead Sponsor
Genentech, Inc.
INDUSTRY